Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM (1999) The biology of chronic myeloid leukemia. New Engl J Med 341(3):164–172. https://doi.org/10.1056/NEJM199907153410306

Article  CAS  PubMed  Google Scholar 

Sawyers CL, Druker B (1999) Tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J Sci Am 5(2):63–69

CAS  PubMed  Google Scholar 

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen J, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saussele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966–984. https://doi.org/10.1038/s41375-020-0776-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leukemia NCM (2022) Version 3.2022, NCCN Clinical Practice guidelines in Oncology. Chronic Myeloid Leukemia. NCCN

Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Garcia-Gutierrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bedoucha V, Hochhaus A (2021) A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138(21):2031–2041. https://doi.org/10.1182/blood.2020009984

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen J, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D (2024) Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after >/=1 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia 38(7):1522–1533. https://doi.org/10.1038/s41375-024-02278-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP, Investigators AF (2024) Asciminib in newly diagnosed chronic myeloid leukemia. New Engl J Med 391(10):885–898. https://doi.org/10.1056/NEJMoa2400858

Article  CAS  PubMed  Google Scholar 

Tran P, Hanna I, Eggimann FK, Schoepfer J, Ray T, Zhu B, Wang L, Priess P, Tian X, Hourcade-Potelleret F, Einolf HJ (2020) Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects. Xenobiotica 50(2):150–169. https://doi.org/10.1080/00498254.2019.1594449

Article  CAS  PubMed  Google Scholar 

Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY (2022) Population Pharmacokinetics of Asciminib in tyrosine kinase inhibitor-treated patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic and Acute Phases. Clin Pharmacokinet 61(10):1393–1403. https://doi.org/10.1007/s40262-022-01148-9

Article  CAS  PubMed  Google Scholar 

Center for Drug Evaluation and Research (2021) NDA/BLA Multi-disciplinary review and evaluation (NDA 215358), Scemblix (Asciminib). Application number: 21538Orig1s000 and 21538Orig2s000. Food and Drug Administration

Elmeliegy M, Yang DZ, Salama E, Parivar K, Wang DD (2021) Discordance between Child-Pugh and National Cancer Institute Classifications for hepatic dysfunction: implications on dosing recommendations for oncology compounds. J Clin Pharmacol 61(1):105–115. https://doi.org/10.1002/jcph.1702

Article  CAS  PubMed  Google Scholar 

Jonsson EN, Karlsson MO (1998) Automated covariate model building within NONMEM. Pharmaceut Res 15(9):1463–1468

Article  CAS  Google Scholar 

Geissler J, Sharf G, Bombaci F, Daban M, De Jong J, Gavin T, Pelouchova J, Dziwinski E, Hasford J, Hoffmann VS (2017) Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol 143(7):1167–1176. https://doi.org/10.1007/s00432-017-2372-z

Article  PubMed  Google Scholar 

Combes FP, Li YF, Hoch M, Lorenzo S, Ho YY, Sy SKB (2022) Exposure-efficacy analysis of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Clin Pharmacol Ther 112(5):1040–1050. https://doi.org/10.1002/cpt.2699

Article  CAS  PubMed  Google Scholar 

Combes FP, Sy SKB, Li YF, Lorenzo S, Dasgupta K, Kapoor S, Hoch M, Ho YY (2024) Dose justification for asciminib in patients with Philadelphia chromosome-positive chronic myeloid leukemia with and without the T315I mutation. Clin Pharmacokinet 63(9):1301–1312. https://doi.org/10.1007/s40262-024-01411-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manley PW, Barys L, Cowan-Jacob SW (2020) The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res 98:106458. https://doi.org/10.1016/j.leukres.2020.106458

Article  CAS  PubMed  Google Scholar 

Hoch M, Huth F, Manley PW, Loisios-Konstantinidis I, Combes FP, Li YF, Fu Y, Sy SKB, Obourn V, Chakraborty A, Hourcade-Potelleret F (2024) Clinical pharmacology of asciminib: a review. Clin Pharmacokinet 63(11):1513–1528. https://doi.org/10.1007/s40262-024-01428-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, Dodd S, Drueckes P, Fabbro D, Gabriel T, Groell JM, Grotzfeld RM, Hassan AQ, Henry C, Iyer V, Jones D, Lombardo F, Loo A, Manley PW, Pelle X, Rummel G, Salem B, Warmuth M, Wylie AA, Zoller T, Marzinzik AL, Furet P (2018) Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem 61(18):8120–8135. https://doi.org/10.1021/acs.jmedchem.8b01040

Article  CAS  PubMed  Google Scholar 

Hoch M, Sato M, Zack J, Quinlan M, Sengupta T, Allepuz A, Aimone P, Hourcade-Potelleret F (2021) Pharmacokinetics of asciminib in individuals with hepatic or renal impairment. J Clin Pharmacol 61(11):1454–1465. https://doi.org/10.1002/jcph.1926

Article  CAS  PubMed  Google Scholar 

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen J, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW (2019) Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. New Engl J Med 381(24):2315–2326. https://doi.org/10.1056/NEJMoa1902328

Article  CAS  PubMed  Google Scholar 

Schulze JJ, Lundmark J, Garle M, Skilving I, Ekstrom L, Rane A (2008) Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab 93(7):2500–2506. https://doi.org/10.1210/jc.2008-0218

Article  CAS  PubMed  Google Scholar